Quizartinib; AC-010220; AC-220

Chemical Name:

N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea

SMILES Code: 

O=C(NC1=CC=C(C2=CN3C(SC4=CC(OCCN5CCOCC5)=CC=C34)=N2)C=C1)NC6=NOC(C(C)(C)C)=C6

InChi Code:

InChI=1S/C29H32N6O4S/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22-18-35-23-9-8-21(16-24(23)40-28(35)31-22)38-15-12-34-10-13-37-14-11-34/h4-9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36)

InChi Key:

CVWXJKQAOSCOAB-UHFFFAOYSA-N

Keyword:

Quizartinib, AC-010220, AC010220, AC 010220, AC-220, AC220, AC 220, 950769-58-1

Solubility: Soluble in DMSO

Storage: 0 - 4°C for short term (days to weeks), or -20°C for long term (months)

Description: 

Quizartinib is an inhibitor of FMS-related tyrosine kinase 3 (FLT3; Kd = 1.6 nM) and demonstrates high selectivity for FLT3 when tested against a panel of 227 additional kinases. It inhibits the proliferation of the human leukemia cell line MV4-11, which harbors a homozygous FLT3-ITD mutation, with an IC50 value of 0.56 nM.1 At 1 mg/kg/day, quizartinib has been shown to extend survival in a mouse model of FLT3-ITD acute myeloid leukemia and to eradicate tumors in an FLT3-dependent mouse xenograft model at 10 mg/kg.

Target: FLT3